NEL ASA | Balance Sheet

Fiscal year is January-December. All values NOK Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
11
98
315
225
295
350
Total Accounts Receivable
3
20
51
38
138
124
Inventories
-
6
15
36
139
135
Other Current Assets
-
-
-
-
12
29
Total Current Assets
15
125
381
300
584
637
Net Property, Plant & Equipment
-
5
17
46
96
135
Total Investments and Advances
-
-
7
14
27
72
Intangible Assets
-
109
411
403
1,018
1,100
Other Assets
-
-
-
-
-
-
Total Assets
15
239
816
763
1,726
1,944
ST Debt & Current Portion LT Debt
-
-
-
-
2
Accounts Payable
-
3
17
17
65
Income Tax Payable
-
-
-
-
-
Other Current Liabilities
6
17
32
47
149
Total Current Liabilities
7
20
49
66
214
Long-Term Debt
-
8
12
10
7
Provision for Risks & Charges
-
-
3
3
8
Deferred Taxes
-
16
21
14
68
Other Liabilities
-
-
-
-
20
Total Liabilities
7
43
85
92
316
Common Equity (Total)
9
196
731
671
1,409
Total Shareholders' Equity
9
196
731
671
1,409
Total Equity
9
196
731
671
1,409
Liabilities & Shareholders' Equity
15
239
816
763
1,726

About NEL ASA

View Profile
Address
Karenslyst allé 20
Oslo PS 0278
Norway
Employees -
Website http://www.nel-asa.com
Updated 07/08/2019
NEL ASA develops diagnostic tests for the early detection of diseases based on gene expression signatures in blood samples. It operates through the In vitro diagnostic (IVD) and hydrogen segments. The In vitro diagnostic segment consists of developing innovative and patient friendly IVD products for early detection of diseases.